X
All Data
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
Lead Product(s): Vesatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: GS-9620
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
Details:
HTI-based vaccines as a component of combination cure regimens are being evaluated in the ongoing AELIX-003 clinical trial testing HTI in combination with Gilead’s investigational TLR7 agonist vesatolimod, in people living with HIV on ART.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
